| Literature DB >> 30412402 |
Eric A Voight1, Brian S Brown1, Stephen N Greszler1, Geoff T Halvorsen1, Gang Zhao1, Albert W Kruger2, John Hartung2, Kirill A Lukin2, Steven R Martinez2, Eric G Moschetta2, Michael T Tudesco2, Nathan D Ide2.
Abstract
ABBV-168 is a dihalogenated nucleotide under investigation for the treatment of hepatitis C virus. Three synthetic routes aimed at achieving the stereoselective installation of the C2' gem-Br,F substitution and subsequent Vorbruggen glycosylation were explored to prepare the penultimate nucleoside intermediate. Development culminated in a route to ABBV-168 featuring a de novo chromatography-free furanose synthesis, protecting group-directed Vorbruggen glycosylation, and highly selective phosphoramidation to furnish the API.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30412402 DOI： 10.1021/acs.joc.8b02341
Source DB: PubMed Journal: J Org Chem ISSN： 0022-3263 Impact factor: 4.354